Request Info


Ask for our annual reports or more information
Email Us

Email Alerts

Sign up for email alerts
Email Alerts
Investor Relations

News Releases

RSS RSS Feeds
News Release Search
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998
DateTitle  
11/15/2006Meridian Bioscience Reports Record Fiscal 2006 Operating Results, Increases Regular Cash Dividend Rate, and Reaffirms Guidance
CINCINNATI--(BUSINESS WIRE)--Nov. 15, 2006--Meridian Bioscience, Inc. (NASDAQ:VIVO): GENERAL HIGHLIGHTS Meridian Bioscience, Inc. (NASDAQ:VIVO) today: reported record fiscal 2006 net sales of $108.4 million and record diluted earnings per share of $0.68, respective increases of 17% and 31% over the prior fiscal year; reported record fourth quarter fiscal 2006 net sales of $28.7 million and diluted earnings per share of $0.18, respecti... 
 Printer Friendly Version
10/25/2006Meridian Licenses Molecular Test Technology from Eiken Chemical Co., Ltd.
CINCINNATI--(BUSINESS WIRE)--Oct. 25, 2006--Meridian Bioscience, Inc., (NASDAQ:VIVO) announced that it has completed a license agreement with Eiken Chemical Co., Ltd., Japan, for its "LAMP" (Loop-mediated Isothermal Amplification) technology. The LAMP technology is a cutting-edge nucleic acid amplification method that is simple to perform, rapid, highly specific and performed at a single temperature. Unlike other amplification methods, no specialized equipment is necessary to perform ... 
 Printer Friendly Version
10/17/2006Meridian Bioscience Again Recognized by Forbes as One of the 200 Best Small Companies
CINCINNATI--(BUSINESS WIRE)--Oct. 17, 2006--Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that it has been recognized by Forbes as one of "The 200 Best Small Companies" for the fourth year in a row. The 200 Best Small Companies list is selected following a comprehensive evaluation of financial results plus additional operating factors of candidate companies having sales between $5 million and $750 million. Additional qualification criteria included a consistent pattern of po... 
 Printer Friendly Version
9/21/2006Meridian Bioscience to Present at UBS Global Life Science Conference
CINCINNATI--(BUSINESS WIRE)--Sept. 21, 2006--Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that the Company has been invited to present at the UBS Global Life Sciences Conference, Tuesday, September 26, 2006 at 1:30 p.m. ET at the Grand Hyatt New York in New York City. Bill Motto, Chairman and CEO and Jack Kraeutler, President and COO, are scheduled to present. A question and answer session will follow and some of the information provided during the session may not have been... 
 Printer Friendly Version
8/14/2006Meridian Partners with Merck KGaA/Germany to Develop New Products
CINCINNATI--(BUSINESS WIRE)--Aug. 14, 2006--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that it has entered into a partnership agreement with the Performance & Life Science Chemicals Division of Merck KGaA, Darmstadt, Germany and its American company EMD. This strategic partnership is focused on the development of new assays for the clinical market, which Meridian will sell through its established, best-in-class sales force and distribution partners. This... 
 Printer Friendly Version
8/9/2006Meridian Bioscience Provides Sales and Earnings Guidance for Fiscal 2007 and Reaffirms Fiscal 2006 Guidance
CINCINNATI--(BUSINESS WIRE)--Aug. 9, 2006--Meridian Bioscience, Inc., (NASDAQ:VIVO) today provided the financial community with guidance regarding the Company's fiscal 2007 sales and earnings estimates. Based on the Company's business planning and budgeting activities for the fiscal year ending September 30, 2007, management expects net sales to be in the range of $118 to $123 million and per share diluted earnings to be between $0.83 and $0.87. The per share estimates assume an incre... 
 Printer Friendly Version
7/20/2006Meridian Bioscience Reports Record Operating Results, Declares Regular Cash Dividend, Reaffirms Higher Fiscal 2006 Guidance, and Comments on Fiscal 2007 Outlook
CINCINNATI--(BUSINESS WIRE)--July 20, 2006--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today: reported record third quarter and nine-month sales of $26,583,000 and $79,763,000, respectively, an increase of 5% and 17% over the same periods of the prior fiscal year; reported record third quarter and nine-month operating income of $6,893,000 and $20,040,000, respectively, an increase of 21% and 39% over the same periods of the prior ... 
 Printer Friendly Version
7/6/2006Meridian Bioscience Announces Its Inclusion in the New NASDAQ Global Select Market - The Market With the Highest Initial Listing Standards in the World -
CINCINNATI, Jul 06, 2006 (BUSINESS WIRE) -- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that it is included in the new NASDAQ Global Select Market. The NASDAQ Global Select Market has the highest initial listing standards of any exchange in the world based on financial and liquidity requirements. Prior to the change, the company had been listed on the NASDAQ National Market. Beginning July 3, NASDAQ-listed companies will be classified under three listing ti... 
 Printer Friendly Version
6/26/2006FORTUNE Small Business Ranks America's Fastest-Growing Small Companies
CINCINNATI--(BUSINESS WIRE)--June 26, 2006--FORTUNE Small Business announced today that Meridian Bioscience, Inc. (NASDAQ:VIVO) has been ranked 66 on the sixth annual FSB 100 list of the fastest growing small companies in America. The list, which is comprised of public companies, appears in the July/August issue of FORTUNE Small Business and is available at FSB.com. John A. Kraeutler, President and Chief Operating Officer, stated, "We would like to thank FORTUNE Small Business for... 
 Printer Friendly Version
6/15/2006Meridian Bioscience to Present at the InvesTristate Regional Public Company Investment Conference
CINCINNATI--(BUSINESS WIRE)--June 15, 2006--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that the Company has been invited to present at the InvesTristate Regional Public Company Investment Conference on Tuesday, June 20, 2006 at 10:55 a.m. ET at the Hyatt Regency, Cincinnati, Ohio. Jack Kraeutler, President and Chief Operating Officer and Melissa Lueke, Vice President and Chief Financial Officer, are scheduled to present. A question and answer session wil... 
 Printer Friendly Version
6/12/2006Meridian Bioscience Receives FDA CLIA Waiver Status for Stomach Ulcer Test
CINCINNATI--(BUSINESS WIRE)--June 12, 2006--Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that it has received CLIA waiver status from the U.S. Food and Drug Administration (FDA) for its ImmunoCard STAT!(R) HpSA test, a rapid single-use test for the diagnosis of Helicobacter pylori (H. pylori) infection. The vast majority of peptic ulcer disease is caused by infection with H. pylori bacteria and, in recent years, effective therapies have become available for eradicating this... 
 Printer Friendly Version
5/5/2006Meridian Bioscience to Present at the Robert W. Baird 2006 Growth Stock Conference
CINCINNATI, May 05, 2006 (BUSINESS WIRE) -- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that the Company has been invited to present at the Robert W. Baird 2006 Growth Stock Conference on Tuesday, May 9, 2006 at 12:40 p.m. CDT at the Four Seasons Hotel in Chicago. Bill Motto, Chairman and Chief Executive Officer and Jack Kraeutler, President and Chief Operating Officer, are scheduled to present. A question and answer session will follow and some of the inform... 
 Printer Friendly Version
5/3/2006Meridian Bioscience Added to Mergent's Dividend Achievers Index(TM)
CINCINNATI--(BUSINESS WIRE)--May 3, 2006--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that it has been added to Mergent's Dividend Achievers Index(TM) for 2006. This index is made up of just 3% of U.S. publicly traded companies with the most consistent records of annual dividend increases. Quoting from Mergent's correspondence, "This designation means that you (Meridian Bioscience, Inc.) are part of an elite class of companies that have successfully d... 
 Printer Friendly Version
4/20/2006Meridian Bioscience Reports Record Second Quarter and Six Months Operating Results, Increases Fiscal 2006 Guidance, and Declares Regular Cash Dividend General Highlights
CINCINNATI, Ohio--(BUSINESS WIRE)--April 20, 2006--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today: reported record second quarter and six months net sales of $28,272,000 and $53,180,000, respectively, an increase of 19% and 25% over the same periods of the prior fiscal year; reported record second quarter and six months net earnings of $4,723,000 and $8,685,000, respectively, an increase of 48% and 64% over the same periods of t... 
 Printer Friendly Version
4/12/2006Meridian Bioscience Helicobacter Pylori Patent Validated by Settlement Agreement With Astra S.r.l.
CINCINNATI--(BUSINESS WIRE)--April 12, 2006--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that it has executed a settlement agreement with Astra S.r.l. regarding Meridian's patented technology for detecting H. pylori, the primary cause of peptic ulcers. In the agreement, Astra acknowledges the existence, validity and scope of Meridian's patent, EPO 0806667. Astra further agrees to: 1) cease all promotion and distribution of its infringing products, and; 2)... 
 Printer Friendly Version
3/16/2006Meridian Bioscience Receives FDA Clearance for New Stomach Ulcer Test
CINCINNATI--(BUSINESS WIRE)--March 16, 2006--Meridian Bioscience, Inc., (NASDAQ:VIVO) today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to market Premier Platinum HpSA(R) Plus, an improved new test for the diagnosis of Helicobacter pylori (H. pylori) infection. The vast majority of peptic ulcer disease is caused by infection with H. pylori bacteria and, in recent years, effective therapies have become available for eradicating this disease... 
 Printer Friendly Version
2/24/2006Meridian Bioscience Named Founding Member to New NASDAQ Dividend Achievers Index
CINCINNATI--(BUSINESS WIRE)--Feb. 24, 2006--Meridian Bioscience, Inc., (NASDAQ:VIVO) today announced that it has been included in the new NASDAQ Dividend Achievers Index as a founding member. Quoting, in part, from the February 22, 2006 press release of the NASDAQ Stock Market, Inc. The NASDAQ Dividend Achievers Index is designed to track the performance of U.S. companies that are listed on NASDAQ and meet Dividend Achievers requirements of increased annual regular ... 
 Printer Friendly Version
1/19/2006Meridian Bioscience Reports Record First Quarter Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2006 Guidance
CINCINNATI, Jan 19, 2006 (BUSINESS WIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO): GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio today: reported record first quarter net sales of $24,908,000, a 32% increase over the same period of the prior fiscal year; reported record first quarter net earnings of $3,962,000, an 88% increase over the same period of the prior fiscal year; reported record first quarter diluted per share earnings of ... 
 Printer Friendly Version